Publications by authors named "I Pateras"

Epithelioid hemangioendothelioma (EHE) is a rare malignant vascular tumor whose pleural EHE (pEHE) type is even more uncommon, with significant heterogeneity in the clinical behavior as well as challenging diagnosis and treatment decisions. Herein, we present a 74-year-old woman admitted to the hospital with dyspnea, pleural effusion, and refractory euvolemic hyponatremia. Chest computed tomography revealed a large right-side pleural effusion with irregular thickening of the parietal pleura and localized nodularity.

View Article and Find Full Text PDF
Article Synopsis
  • In situ hybridization is a method used to visualize RNA in cells, but analyzing images can be complicated.
  • The presented protocol utilizes open-source software for automating the analysis of multiple RNA probes (up to 14) in fluorescence in situ transcriptomics.
  • Key steps involve segmenting cell nuclei, storing raw data, ensuring quality control, and using a Python app to compile results into a comprehensive spreadsheet that shows cell positivity.
View Article and Find Full Text PDF

We present a 39-centimeter thecoma with ascites and elevated Ca-125 values which is compatible with an atypical/incomplete Meigs' syndrome. Giant ovarian masses with elevated Ca-125 values and ascites are an alarming combination, although Gynecologists should be aware that there are also benign entities that mimic advanced stage ovarian cancer.

View Article and Find Full Text PDF

Breast carcinoma is the most common cancer in women. Nineteen different subtypes of breast carcinomas are recognized in the current WHO classification of breast tumors. Except for these subtypes, there are a number of carcinomas with special morphologic and immunohistochemical features that are not included in the 5th WHO classification, while others are considered special morphologic patterns of invasive breast carcinoma of no special type.

View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 52 stage III/IV NSCLC patients showed that 44% had detectable pre-existing T cells specific to tumors, and those patients had better median overall survival rates compared to those without these T cells.
  • * The research highlighted that patients with pre-existing T cells and low levels of certain immunosuppressive cells had a significant survival advantage, suggesting that evaluating these immune cell characteristics could help identify which patients are likely to benefit most from immunotherapy.
View Article and Find Full Text PDF